Indianapolis, Indiana-based Eli Lilly and Company (LLY) discovers, develops, manufactures, and markets human pharmaceutical products in the United States and internationally. The company has a market cap of\u00a0$900.7 billion and offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75\/25, Humalog U-100, Humalog U-200, Humalog Mix 50\/50, and more.<\/p>\n
LLY is expected to release its\u00a0Q1 2026 earnings on Thursday, Apr. 30, before the market opens. Ahead of the event, analysts expect the company\u2019s\u00a0EPS to be $7.55 on a diluted basis, up 126.1% from $3.34 in the year-ago quarter. The company has exceeded Wall Street\u2019s EPS estimates in three of its last four quarters, while missing on one occasion.<\/p>\n
For fiscal 2026, analysts project the company\u2019s EPS to be $34.73, up 43.5%\u00a0from $24.21 in fiscal 2025. Moreover, its EPS is expected to rise by roughly 20.6% year over year (YoY) to $41.89 in fiscal 2027.<\/p>\n LLY stock has surged\u00a025.5% over the past 52 weeks, outperforming the S&P 500 Index\u2019s ($SPX)\u00a024.1% rise and the State Street Healthcare Select Sector SPDR ETF\u2019s (XLV)\u00a07.2% rise during the same time frame.<\/p>\n LLY stock has grown consecutively in three trading sessions from the end of March to the start of this month. The reason behind the growing interest in the stock from the investors lies in its\u00a0fundamentals. LLY boasts an impressive 38.2% annual revenue growth over the last two years, which indicates a winning market share in this cycle. Moreover, its adjusted operating margin has improved by 21.2% over the past two years, showcasing its ability to scale efficiently.<\/p>\n Analysts are highly bullish on LLY, with the stock having a \u201cStrong Buy\u201d rating overall. Among the 30 analysts covering the stock, 23 are recommending a \u201cStrong Buy,\u201d three recommend a \u201cModerate Buy,\u201d and four suggest a \u201cHold.\u201d LLY\u2019s average analyst price target is $1,239.50, indicating an upside of 30.6% from the current levels.<\/p>\n On the date of publication, Aritra Gangopadhyay did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally\u00a0published on Barchart.com <\/i><\/p>\n<\/p><\/div>\n<\/div>\n<\/div>
<\/div>\n<\/div>